Monograph Capital
Overview
Monograph Capital is a venture firm focused on life sciences. With a dedicated emphasis on the life sciences sector, Monograph Capital invests in innovative companies and technologies that aim to advance healthcare and biotechnology. The firm supports early-stage ventures as well as growth-stage companies, providing critical capital, strategic guidance, and industry expertise to drive their development and success . Monograph Capital's investments span across biotech, pharmaceuticals, medical devices, and other areas within the life sciences field, aiming to contribute to breakthrough discoveries, therapies, and medical advancements . Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Nocion Therapeutics | Jan 2026 | Series B Extension | Lead |
| ProLynx Inc. | Dec 2025 | Series A | Lead |
| Elevara Medicines | Oct 2025 | Series A | Co-investor |
| Ollin Biosciences, Inc. | Sep 2025 | Series A | Lead |
| Maxion Therapeutics | Mar 2025 | Series A | Co-investor |
Key People
Charles Conn
Co-founder And Partner, Monograph Capital
Jo T.
EA To Founder And Partner (Start Up Life Science VC)
Tim Funnell
Partner
Bonnie van Wilgenburg
Principal
Freddie Dear
Principal
Jaideep Dudani
Principal
Charlie Zhou
Investment Manager
Melisa Guven
Investment Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.